ClinicalTrials.gg
CompletedNCT00307008Updated Apr 15, 2013

Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.

A Phase 2 interventional study of Pneumovax 23™ in Streptococcus Pneumoniae Vaccines, sponsored by GlaxoSmithKline. Completed at 5 sites in Sweden. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-04-15.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,198
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Pneumonia by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Pneumonia · GlaxoSmithKline.

Enrollment
5th of 10
1,198 · median 794
Started
2003
the only one that year
Phase 2
3 of 13
none open now
Registered
2nd of 13
by date

Among the 13 studies in Pneumonia by GlaxoSmithKline, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2003, is one of 3 in phase 2, and was the 2nd registered.

Pneumonia

1,568 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

None of the 13 studies in Pneumonia by GlaxoSmithKline is open now. The open studies under Pneumonia, anywhere →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 85 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 41 take children under 18; 24 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Pneumonia by GlaxoSmithKline as a file.
02

Study summary

Streptococcus pneumoniae are bacteria which normally live in the upper respiratory tract of humans. However, these bacteria can also cause severe infectious diseases such as pneumonia, septicemia and meningitis. Elderly subjects are especially vulnerable to these infections, and the diseases can result in death. The currently available licensed Streptococcus pneumoniae vaccine is recommended for prevention of pneumococcal diseases in individuals over the age of 65. However, the antibody level elicited by this vaccine, is not always satisfactory in elderly people. To overcome the problem, GlaxoSmithKline Biologicals is currently developing candidate vaccines that are hoped to work better than the currently available vaccines. As a first step in this development, the present study is being conducted in order to evaluate the immune response to the currently marketed vaccine.

Read the detailed description

Since influenza vaccination is recommended in the age range of the study population, Fluarix™ (GlaxoSmithKline Biologicals) vaccine will be offered free of charge for the study period (3 consecutive years), to be used by Investigators according to national vaccination schedule/practice.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007

03

Conditions studied

  • Streptococcus Pneumoniae Vaccines

Browse trials for

Keywords

  • Prophylaxis Invasive pneumococcal diseases and pneumonia
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes will comply with the requirements of the protocol.
  • A male or female >= 65 years at the time of the first vaccination.
  • Written obtained from the subject.

Exclusion criteria

Exclusion criteria

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period or participation to another pharmaceutical/vaccine study.
  • Previous vaccination against Streptococcus pneumoniae.
  • History of administration of an experimental vaccine containing MPL or QS21.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Planned administration of a vaccine not foreseen by the study protocol within 2 weeks before and after first dose of vaccines, excluding influenza vaccine which can be administered at any time, including co-administration with Pneumovax23™.
  • Chronic administration of or other immune-modifying drugs within six months prior to the first vaccine dose.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including (HIV) infection.
  • Current serious neurologic or mental disorders.
  • Inflammatory processes such as known chronic active infections (e.g.Hep B, C).
  • All (excluding non-melanic skin cancer) and lymphoproliferative disorders diagnosed or treated actively during the past 5 years.
  • Acute disease at the time of enrolment.
  • Chronic disease that might preclude participation to the whole study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,198 participants (actual)

Study arms

  • Experimental
    Group A

    Biological: Pneumovax 23™

Interventions

06

What researchers measure

Primary outcomes

  1. Response rate to 11 vaccine serotypes

    Time frame: One month post vaccination

Secondary outcomes

  1. Anti-polysaccharide total IgG ELISA for 11 vaccine pneumococcal serotypes

    Time frame: At all time points

  2. Opsonophagocytic activity against 11 vaccine pneumococcal serotypes in a subset of subjects

    Time frame: At Day 0 and Day 30.

  3. The rank of subjects from "poorest responder" to "best responder" based on the number of serotypes each subject responds to

    Time frame: One month post vaccination

  4. Persistence of the immune response in a subset of subjects.

    Time frame: Until Month 36.

  5. Opsonophagocytic activity response in a subset of subjects.

    Time frame: At Day 30

  6. Occurrence of serious adverse events (SAE).

    Time frame: Up to 1 month after vaccination.

  7. Occurrence of study related SAEs.

    Time frame: Throughout the study period.

07

Study locations

5 sites
  • GSK Investigational Site
    Eskilstuna, SE-631 88, Sweden
  • GSK Investigational Site
    Jönköping, SE-551 85, Sweden
  • GSK Investigational Site
    Skövde, SE-541 85, Sweden
  • GSK Investigational Site
    Uppsala, SE-751 85, Sweden
  • GSK Investigational Site
    Västerås, SE 721 89, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Feb 2005 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2006
First posted
Mar 27, 2006
Start
Oct 2003
Primary completionActual
Feb 2005
CompletionActual
Feb 2005
Last update
Apr 15, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00307008
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 27, 2006
Start date
Oct 2003
Primary completion
Feb 2005
Completion
Feb 2005
Last update
Apr 15, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine

Start the discussion